TCL-089: Clinicopathological Presentation of Peripheral T-Cell Lymphoma and Their Prognostic Factors: A Single Center Experience

Background Peripheral T-cell lymphomas (PTCLs) represent an uncommon and heterogeneous group of diseases. They comprise 10-15% of NHL, with epidemiological majority in South American and Asian populations. Historically these groups of malignancies have presented a poor prognosis, however, with the incorporation of brentuximab and autologous stem cell transplantation (ASCT) as consolidation strategy, the overall survival has improved. Objectives Describe the clinicopathological presentation of patients with PTLCs and review their prognosis features. Design Retrospective, observational study that included patients over 18 years with diagnosis of PTLCs, between January 2010 and December 2019. All of them were followed up at the HIBA. Results We included 43 patients with PTLCs diagnosis. The median age was 58 years (range 20-90) and 65% were male. The most common histopathological subtype was PTLC-NOS in 42% (n=18) followed by ALCL ALK- and AITL with 23% (n=10) and 14% (n=6) respectively. The 81% presented III/IV stage at the diagnosis and 58% had evidence of extranodal disease. Considering IPI and PIT scores, high risk populations slightly differ from 53% in the first score to 44% in the other. Nearly 80% of the patients received protocols including anthracyclines such as CHOEP in 44% (n=19) or CHOP in 32% (n=14) as first line treatment. Another 7% used brentuximab + CHP and 41% (n=18) of the total underwent ASCT as consolidation therapy. Almost 58% achieved complete remission. The overall survival (OS) at 5 years was 37% (IC 95% 20-56) with a median of 36 months. Variables significantly associated with OS were age range (48% vs 26% in under 60 years; p=0,12) and IPI score (65% vs 25% in low-risk groups; p=0.0044). Moreover, ASCT was associated with better OS and PFS with 61% and 58% respectively; versus 26% and 28% in the group without transplant (p=0,0064). Conclusions In our experience, PTLCs represent an ominous diagnosis with high mortality in older people and high-risk groups. ASCT showed improvement in OS. Nevertheless, the implementation of brentuximab is still being studied because of the few patients receiving this therapy at the moment.